Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients with triple negative subtype who achieved pCR after neoadjuvant treatment would have longer survival. The neoadjuvant treatment for her2 negative patient was chemotherapy with combined drugs. However, not all patients benefit from chemotherapy but suffer from chemotherapy-related side effects. It was unknown for a patient who could benefit from which drug before chemotherapy. Drug sensitivity screening in vitro was a promising method for choosing chemotherapy. But there was no method could select effecti

Trial Details

NCT ID
NCT04836156
Phase
PHASE1 / PHASE2
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
  • neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • invasive breast cancer
  • HER2 negative
  • T2 or node positive
  • Eastern Cooperative Oncology Group(ECOG) 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →